Pay attention to the detection and treatment of ocular gene therapy viral vector-associated immunity
10.3760/cma.j.cn511434-20220629-00389
- VernacularTitle:重视眼部基因治疗病毒载体相关免疫的监测与处理
- Author:
Xiaodong SUN
1
;
Jieqiong CHEN
Author Information
1. 上海交通大学附属第一人民医院眼科 国家眼部疾病临床医学研究中心 上海市眼底病重点实验室 上海眼视觉与光医学工程技术研究中心, 上海 200080
- Keywords:
Gene therapy;
Inflammation;
Vector-associated immunity;
Editorial
- From:
Chinese Journal of Ocular Fundus Diseases
2022;38(8):621-625
- CountryChina
- Language:Chinese
-
Abstract:
The application of gene therapy in ocular diseases is gradually expanding from mono-gene inherited diseases to multigene, multifactorial, common and chronic diseases. This emerging therapeutic approach is still in the early exploratory stage of treating diseases, and the expected benefits and risks remain highly uncertain. In the delivery process of gene therapy drugs, viral vector is currently one of the most mature and widely used vectors. The occurrence of vector-associated immunity will affect the short-term and long-term effects of gene therapy, and even cause permanent and serious damage to visual function. Therefore, gene therapy vector-associated immunity is the focus and challenge for the safety and long-term efficacy of gene therapy. During the perioperative and follow-up of gene therapy, attention should be paid to the monitoring of vector-associated immune inflammation, and appropriate measures should be taken to deal with the corresponding immune response, so as to achieve the best visual benefits for patients.
